Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Changes in gut microbiota and risk of colitis associated with immune checkpoint inhibitors

FY 2018-19

Summary
Immune checkpoint inhibitors (ICI) are a class of drugs which relieve suppression of the immune system to induce an anti-tumour immune response in cancer patients. Despite the rise in usage and efficacy of ICI in mainstream cancer therapy, many patients still fail to achieve an adequate response towards the drug, and toxicities associated with ICI, such as colitis, remain common in treated patients. Recently, interactions between regular gut bacteria and tumor response have been well studied largely due to the gut microbiome being implicated as a modulator of systemic immune responses. Thus, this project seeks to identify gut bacteria which may be contributing towards the therapeutic efficacy and toxicities associated with ICIs. My hypothesis is that tumor response and risk of colitis can be predicted by baseline differences between gut bacteria in cancer patients, and that changes in bacteria caused by ICI can improve tumor response and/or induce the development of colitis. Using fecal samples obtained from metastatic melanoma patients, we plan on identifying gut bacteria at baseline before ICI treatment. We will compare this to post-treatment bacterial profiles to identify any changes. Additionally, harmful bacteria causing colitis will be identified post-treatment to determine which specific bacteria induced by ICIs contribute to colitis development. This study is important as there are currently inconclusive findings over which bacteria are predictive of tumor responses after ICI treatment. The involvement of patients from separate institutions may provide clarity on which bacteria contribute towards tumor responses. Determining bacteria associated with post-ICI colitis will also help with the identification of patients at high risk of colitis.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
406322
Name
Wong Matthew
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Changes in gut microbiota and risk of colitis associated with immune checkpoint inhibitors
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Checkpoint Inhibitors; Colitis; Drug-Associated Toxicities; Gut Microbiome; Metastatic Melanoma; Tumor Immunotherapy
Abstract
Immune checkpoint inhibitors (ICI) are a class of drugs which relieve suppression of the immune system to induce an anti-tumour immune response in cancer patients. Despite the rise in usage and efficacy of ICI in mainstream cancer therapy, many patients still fail to achieve an adequate response towards the drug, and toxicities associated with ICI, such as colitis, remain common in treated patients. Recently, interactions between regular gut bacteria and tumor response have been well studied largely due to the gut microbiome being implicated as a modulator of systemic immune responses. Thus, this project seeks to identify gut bacteria which may be contributing towards the therapeutic efficacy and toxicities associated with ICIs. My hypothesis is that tumor response and risk of colitis can be predicted by baseline differences between gut bacteria in cancer patients, and that changes in bacteria caused by ICI can improve tumor response and/or induce the development of colitis. Using fecal samples obtained from metastatic melanoma patients, we plan on identifying gut bacteria at baseline before ICI treatment. We will compare this to post-treatment bacterial profiles to identify any changes. Additionally, harmful bacteria causing colitis will be identified post-treatment to determine which specific bacteria induced by ICIs contribute to colitis development. This study is important as there are currently inconclusive findings over which bacteria are predictive of tumor responses after ICI treatment. The involvement of patients from separate institutions may provide clarity on which bacteria contribute towards tumor responses. Determining bacteria associated with post-ICI colitis will also help with the identification of patients at high risk of colitis.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Wong, Matthew
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~